Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MREO
STRONG SELLMereo BioPharma Group plc · Healthcare · United Kingdom · $50M · Avg Vol: $395K/d
6
StockRankGet insider-trade alerts
Q
26
V
31
M
19
P/E (TTM)
—
ROE
-75.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 10.0M | 0 | 0.5M | -77.6% | 0.5M | 6.1M | 14.6M | 439.7% |
| EPS | -1.42 | -0.88 | -1.46 | -1.25 | — | -0.20 | — | — | — |
| Shares | 159.6M | 159.6M | 159.6M | 159.6M | 0.0% | 159.6M | — | — | — |
| Debt | 15.4M | 6.0M | 6.4M | 0.2M | -76.4% | — | — | — | — |
| Equity | 51.4M | 50.5M | 61.0M | 40.9M | -7.3% | — | — | — | — |
| Op CF | -48.8M | -21.1M | -32.8M | -31.0M | — | -27.0M | — | — | — |
| Inv CF | 2.0M | -0.4M | -0.7M | -20.0K | — | — | — | — | — |
| Fin CF | 0.2M | 8.0M | 46.1M | 0.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-1.0%
SMA 50SMA 200
Close
$0.302
RSI (14)
37.2
52W High
$2.37
From 52W High
0.1%
SCORE BREAKDOWN
Quality
26
ROIC
-85.6%7.4
ROE
-75.9%12.1
GP/Assets
0.8%12.9
Op. Margin
-7182.2%2.9
FCF/Assets
-68.1%3.4
Piotroski
559.8
Int. Cover
-50.0x6.3
D/E Ratio
0.00x88.6
Current Ratio
6.48x78.0
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-0.4x25.0
P/FCF
—N/A
P/B
1.4x73.4
P/S
97.4x7.7
Div Yield
—N/A
Momentum
19
52W High %
13%1.3
RS 6M
-50%14.4
SMA 50/200
0.38x0.8
EPS Rev 4W
-1.6%19.8
EPS Rev 12W
—N/A
EPS Improve
+81%67.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$50M
P/E (Forward)
-8.0x
Gross Margin
73.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MREO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc(you) | $50M | 6 | STRONG SELL |
| OKYO | OKYO Pharma Limited | $81M | 6 | STRONG SELL |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $70M | 9 | STRONG SELL |
| IMM.L | ImmuPharma plc | $31M | 2 | STRONG SELL |
| APTA.L | Aptamer Group PLC | $25M | 4 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
| SAR.L | Sareum Holdings plc | $38M | 19 | STRONG SELL |
| TLSA | Tiziana Life Sciences Ltd | $114M | 1 | STRONG SELL |
| 4BB.L | 4basebio PLC | $110M | 11 | STRONG SELL |
| POLB.L | Poolbeg Pharma PLC | $63M | 24 | SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 55.5%